The effects of famciclovir and epidural block in the treatment of herpes zoster.
In our previous study, we concluded that an epidural blockade combined with intravenous acyclovir is very effective in treating the acute pain in herpes zoster and postherpetic neuralgia. We evaluated the efficacy of oral famciclovir and epidural blockade on the pain of herpes zoster, compared to acyclovir administered intravenously and epidural blockade. For this purpose, we examined a new group treated with famciclovir and epidural blockade to compare with the group treated with acyclovir and epidural blockade in our previously study. The changes in the intensity of pain, the number of days required for relief of pain, and the total duration of pain were checked. We compared the days required for relief of pain (DRP) and the total duration of pain (TDP) of this group with those of the previous studied group treated with acyclovir and epidural blockade. DRP was significantly less, but TDP was similar. DRP and TDP were significantly lower, if the patients were treated within 7 days of symptom onset. The patients had a shorter DRP regardless of pain type than the previously studied group treated with acycolvir and epidural blockade. For the severe and moderate pain grades, there was a shorter DRP from 100 to 10. TDP was not significantly different for the groups regardless of pain type or grade. We believe that famciclovir and epidural blockade are very effective in treating the pain of herpes zoster, with a view to shortening the period of acute pain, providing similar effects on the prevention of postherpetic neuralgia, and being convenient to administer, compared to intravenous acyclovir and epidural blockade in our previous study.
Ahn
H J
HJ
Department of Dermatology, Yonsei University Wonju College of Medicine, 162 Ilsan-Dong, Wonju, Kangwon-Do 220-701, Republic of Korea.
Lim
H K
HK
Lee
Y B
YB
Hwang
S M
SM
Lee
W S
WS
Ahn
S K
SK
Choi
E H
EH
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D015360:Analgesia, Epidural; D000704:Analysis of Variance; D000779:Anesthetics, Local / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D002045:Bupivacaine / Q000627:therapeutic use; D000077595:Famciclovir; D005260:Female; D006562:Herpes Zoster / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D010147:Pain Measurement; D016896:Treatment Outcome
D000779:Anesthetics, Local; D000998:Antiviral Agents; D015075:2-Aminopurine; D000077595:Famciclovir; D000212:Acyclovir; D002045:Bupivacaine